Comano's (Trentino) thermal water interferes with tumour necrosis factor-α expression and interleukin-8 production and secretion by cultured human psoriatic keratinocytes: Yet other mechanisms of its anti-psoriatic action

International Journal of Molecular Medicine

Volumn 19, Issue 3, 2007, Pages 373-379

  Dal Pra, Ilaria ^a   Chiarini, Anna ^a   Pacchiana, Raffaella ^a   Zumiani, Giuseppe ^b   Zanoni, Mauro ^c   Armato, Ubaldo ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b SANTA CHIARA HOSPITAL   (Italy)

^c Castelfranco TV   (Italy)

Author keywords

Chemokines; Comano's thermal water; Cytokines; Human keratinocytes; Interleukin 8; Psoriasis; Tumour necrosis factor

Indexed keywords

INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA; WATER;

ARTICLE; BALNEOTHERAPY; BIOSYNTHESIS; CELL CULTURE; CHEMISTRY; CYTOLOGY; DOWN REGULATION; DRUG EFFECT; HUMAN; ITALY; KERATINOCYTE; METABOLISM; PATHOLOGY; PSORIASIS; SECRETION;

BALNEOLOGY; CELLS, CULTURED; DOWN-REGULATION; HUMANS; INTERLEUKIN-8; ITALY; KERATINOCYTES; PSORIASIS; TUMOR NECROSIS FACTOR-ALPHA; WATER;

EID: 33947513055     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.19.3.373     Document Type: Article

References (68)

1. Bowcok AM and Krueger JG: Getting under the skin: the immunogenetics of psoriasis. Nat Rev Immunol 5: 699-711, 2005.
2. Bos JD and De Rie MA: The pathogenesis of psoriasis. Immunol Today 20: 40-46, 1999.
3. Telner P and Fekete Z: The capillary responses in psoriatic skin. J Invest Dermatol 36: 225-230, 1961.
4. Creamer D, Allen MH, Sousa A, Poston R and Barker JN: Localization of endothelial proliferation and microvascular expansion in active plaque psoriasis. Br J Dermatol 136: 859-865, 1997. (Pubitemid 27283516)
5. Braverman IM and Sibley J: Role of the microcirculation in the treatment and pathogenesis of psoriasis. J Invest Dermatol 78: 12-17, 1982.
6. Schubert C and Christophers E: Mast cells and macrophages in early relapsing psoriasis. Arch Dermatol Res 277: 352-358, 1985. (Pubitemid 15059775)
7. Folkman J: Angiogenesis in psoriasis: therapeutic implications. J Invest Dermatol 59: 40-43, 1972.
8. Goodfield M, Hull SM, Holland D, Roberts G, Wood E, Reid S and Cunliffe W: Investigations of the 'active' edge of plaque psoriasis: vascular proliferation precedes changes in epidermal keratin. Br J Dermatol 131: 808-813, 1994.
9. Creamer D, Sullivan D, Bicknell R and Barker J: Angiogenesis in psoriasis. Angiogenesis 5: 231-236, 2002.
10. Barnhill RL, Parkinson EK and Ryan TJ: Supernatants from cultured human epidermal keratinocytes stimulate angiogenesis. Br J Dermatol 110: 273-281, 1984.
11. Nickoloff BJ, Mitra RS, Varani J, Dixit VM and Polverini PJ: Aberrant production of interleukin-8 and thrombospondin-1 by psoriatic keratinocytes mediates angiogenesis. Am J Pathol 144: 820-828, 1994.
12. Ettehadi P, Greaves MW, Wallach D, Aderka D and Camp RD: Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol 96: 146-151, 1994.
13. Elder JT, Fisher GJ, Lindquist PB, Bennett GL, Pittelkow MR, Coffey RJ Jr, Ellingsworth L, Derynck R and Voorhees JJ: Overexpression of transforming growth factor alpha in psoriatic epidermis. Science 243: 811-814, 1989.
14. Creamer D, Jaggar R, Allen M, Bicknell R and Barker J: Overexpression of the angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase in psoriatic epidermis. Br J Dermatol 137: 851-855, 1997.
15. Bonifati C and Ameglio F: Cytokines in psoriasis. Int J Dermatol 38: 241-251, 1999.
16. Blumberg H, Conklin D, Xu WF, Grossmann A, Brender T, Carollo S, Eagan M, Foster D, Haldeman BA, Hammond A, Haugen H, Jelinek L, Kelly JD, Madden K, Maurer MF, Parrish-Novak J, Prunkard D, Sexson S, Sprecher C, Waggie K, West J, Whitmore TE, Yao L, Kuechle MK, Dale BA and Chandrasekher YA: Interleukin 20: discovery, receptor identification, and role in epidermal function. Cell 104: 9-19, 2001.
17. Detmar M, Brown LF, Claffey KP, Yeo KT, Kocher O, Jackman RW, Berse B and Dvorak HF: Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 180: 1141-1146, 1994.
18. Bhushan M, McLaughlin B, Weiss JB and Griffiths CE: Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. Br J Dermatol 141: 1054-1060, 1999.
19. Nickoloff BJ, Karabin GD, Barker JN, Griffiths CE, Sarma V, Mitra RS, Elder JT, Kunkel SL and Dixit VM: Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis. Am J Pathol 138: 129-140, 1991.
20. Barker JN, Sarma V, Mitra RS, Dixit VM and Nickoloff BJ: Marked synergism between tumor necrosis factor-alpha and interferon-gamma in regulation of keratinocyte-derived adhesion molecules and chemotactic factors. J Clin Invest 85: 605-608, 1990.
21. Konstantinova NV, Duong DM, Remenyik E, Hazarika P, Chuang A and Duvic M: Interleukin-8 is induced in skin equivalents and is highest in those derived from psoriatic fibroblasts. J Invest Dermatol 107: 615-621, 1996.
22. Gillitzer R, Berger R, Mielke V, Muller C, Wolff K and Stingl G: Upper keratinocytes of psoriatic skin lesions express high levels of NAP-1/IL-8 mRNA in situ. J Invest Dermatol 97: 73-79, 1991.
23. Beljaards RC, Van Beek P, Nieboer C, Stoof TJ and Boorsma DM: The expression of interleukin-8 receptor in untreated and treated psoriasis. Arch Dermatol Res 289: 440-443, 1997.
24. Gillitzer R, Ritter U, Spandau U, Goebeler M and Brocker EB: Differential expression of GRO-alpha and IL-8 mRNA in psoriasis: a model for neutrophil migration and accumulation in vivo. J Invest Dermatol 107: 778-782, 1996.
25. Nickoloff BJ: The cytokine network in psoriasis. Arch Dermatol 127: 871-884, 1991.
26. Kemeny L, Ruzicka T, Dobozy A and Michel G: Role of interleukin-8 receptor in skin. Int Arch Allergy Immunol 104: 317-322, 1994.
27. Tuschil A, Lam C, Haslberger A and Lindley I: Interleukin-8 stimulates calcium transients and promotes epidermal cell proliferation. J Invest Dermatol 99: 294-298, 1992.
28. Lindley I, Aschauer H, Seifert JM, Lam C, Brunowsky W, Kownatzki E, Thelen M, Peveri P, Dewald B, von Tscharner V, Waltz A and Baggiolini M: Synthesis and expression in Escherichia coli of the gene encoding monocyte-derived neutrophil-activating factor: biological equivalence between natural and recombinant neutrophil-activating factor. Proc Natl Acad Sci USA 85: 9199-9203, 1988.
29. Larsen CG, Anderson AO, Appella E, Oppenheim JJ and Matsushima K: The neutrophil-activating protein (NAP-1) is also chemotactic for T lymphocytes. Science 243: 1464-1466, 1989.
30. Leonard EJ, Yoshimura T, Tanaka S and Raffeld M: Neutrophil recruitment by intradermally injected neutrophil attractant/ activation protein-1. J Invest Dermatol 96: 690-694, 1991.
31. Nilsson G, Mikovits JA, Metcalfe DD and Taub DD: Mast cell migratory response to interleukin-8 is mediated through interaction with chemokine receptor CXCR2/Interleukin-8RB. Blood 93: 2791-2797, 1999.
32. Barker JN, Jones ML, Mitra RS, Crockett-Torabe E, Fantone JC, Kunkel SL, Warren JS, Dixit VM and Nickoloff BJ: Modulation of keratinocyte-derived interleukin-8 which is chemotactic for neutrophils and T lymphocytes. Am J Pathol 139: 869-876, 1991.
33. Delaporte E, Bieber T, Viac J, Faure M and Nicolas JF: Cytokines épidermiques et inflammation cutanée. Ann Dermatol Venereol 121: 836-843, 1994.
34. Jacob SE, Nassiri M, Kerdel FA and Vincek V: Simultaneous measurement of multiple Th1 and Th2 serum cytokines in psoriasis and correlation with disease severity. Mediators Inflamm 12: 309-313, 2003.
35. Arican O, Aral M, Sasmaz S and Ciragil P: Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm 14: 273-279, 2005.
36. Bonifati C, Carducci M, Cordiali Fei P, Trento E, Sacerdoti G, Fazio M and Ameglio F: Correlated increases of tumour necrosis factor-alpha, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients - relationships with disease severity. Clin Exp Dermatol 19: 383-387, 1994.
37. Olaniran AK, Baker BS, Paige DG, Garioch JJ, Powles AV and Fry L: Cytokine expression in psoriatic skin lesions during PUVA therapy. Arch Dermatol Res 288: 421-425, 1996.
38. Wakefield PE, James WD, Samlaska CP and Meltzer MS: Tumor necrosis factor. J Am Acad Dermatol 24: 675-685, 1991.
39. Benoit S, Toksoy A, Brocker EB, Gillitzer R and Goebeler M: Treatment of recalcitrant pustular psoriasis with infliximab: effective reduction of chemokine expression. Br J Dermatol 150: 1009-1012, 2004.
40. Gottlieb AB, Chamian F, Masud S, Cardinale I, Abello MV, Lowes MA, Chen F, Magliocco M and Krueger JG: TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol 175: 2721-2729, 2005.
41. Saini R, Tutrone WD and Weinberg JM: Advances in therapy for psoriasis: an overview of infliximab, etanercept, efalizumab, alefacept, adalimumab, tazarotene, and pimecrolimus. Curr Pharm Des 11: 273-280, 2005.
42. Groves RW, Allen MH, Ross EL, Barker JN and MacDonald DM: Tumor necrosis factor alpha is pro-inflammatory in normal human skin and modulates cutaneous adhesion molecule expression. Br J Dermatol 132: 345-352, 1995.
43. Aggarwal BB and Natarajan K: Tumor necrosis factors: developments during the last decade. Eur Cytokine Netw 7: 93-124, 1996.
44. Zumiani G, Zanoni M and Agostini G: Valutazione dell'efficacia dell'acqua della fonte termale di Comano versus acqua di acquedotto nella cura della psoriasi. G Ital Dermatol Venereol 135: 1-5, 2000.
45. Grice KA: Transepidermal water loss in pathological skin. In: Physiology and Pathophysiology of the Skin. Jarret A (ed). Academic Press, London, pp2147-2155, 1980.
46. Harding CR: The stratum corneum: structure and function in health and disease. Dermatol Ther 17 (suppl 1): 6-15, 2004.
47. Madison KC: Barrier function of the skin: 'la raison d'etre' of the epidermis. J Invest Dermatol 121: 231-241, 2003.
48. Tsoureli-Nikita E, Menchini G, Ghersetich I and Hercogova J: Alternative treatment of psoriasis with balneotherapy using Leopoldine spa water. J Eur Acad Dermatol Venereol 16: 260-262, 2002.
49. Chiarini A, Dal Pra I, Pacchiana R, Menapace L, Zumiani G, Zanoni M and Armato U: Comano's (Trentino) thermal water interferes with the expression and secretion of vascular endothelial growth factor-A (VEGF-A) protein isoforms by cultured human psoriatic keratinocytes: A potential mechanism of its anti-psoriatic action. Int J Mol Med 18: 17-25, 2006.
50. Chiarini A, Dal Pra I, Pacchiana R, Zumiani G, Zanoni M and Armato U: Comano's (Trentino) thermal water interferes with interleukin-6 production and secretion and with cytokeratin-16 expression by cultured human psoriatic keratinocytes: Further potential mechanisms of its anti-psoriatic action: Int J Mol Med 18: 1073-1079, 2006.
51. Newby CS, Barr RM, Greaves MW and Mallet AI: Cytokine release and cytotoxicity in human keratinocytes and fibroblasts induced by phenols and sodium dodecyl sulfate. J Invest Dermatol 115: 292-298, 2000.
52. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
53. Sticherling M, Bornscheuer E, Schroder JM and Christophers E: Localization of neutrophil-activating peptide-1/interleukin-8- immunoreactivity in normal and psoriatic skin. Invest Dermatol 96: 26-30, 1991.
54. Barker CL, McHale MT, Gillies AK, Waller J, Pearce DM, Osborne J, Hutchinson PE, Smith GM and Pringle JH: The development and characterization of an in vitro model of psoriasis. J Invest Dermatol 123: 892-901, 2004.
55. Barnes PJ: Nuclear factor-kappa B. Int J Biochem Cell Biol 29: 867-870, 1997.
56. Mussi A, Bonifati C, Carducci M, D'Agosto G, Pimpinelli F, D'Urso D, D'Auria L, Fazio M and Ameglio F: Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis. J Biol Regul Homeost Agents 11: 115-118, 1997.
57. Ameglio F, Bonifati C, Pietravalle M and Fazio M: Interleukin-6 and tumour necrosis factor levels decrease in the suction blister fluids of psoriatic patients during effective therapy. Dermatology 189: 359-363, 1994.
58. Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M, Scallon B, Moore MA, Vilcek J, Daddona P, et al: Construction and initial characterization of a mouse-human chimeric anti- TNF antibody. Mol Immunol 30: 1443-1453, 1993.
59. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG and Gottlieb AB: Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 357: 1842-1847, 2001.
60. Abuzakouk M, Feighery C and Jackson J: Tumour necrosis factor blocking agents: a new therapeutic modality for inflammatory disorders. Br J Biomed Sci 59: 173-179, 2002.
61. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B and Burge DJ: Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet 356: 385-390, 2000.
62. Moss ML, Jin SL, Becherer JD, Bickett DM, Burkhart W, Chen WJ, Hassler D, Leesnitzer MT, McGeehan G, Milla M, Moyer M, Rocque W, Seaton T, Schoenen F, Warner J and Willard D: Structural features and biochemical properties of TNF-alpha converting enzyme (TACE). J Neuroimmunol 72: 127-129, 1997.
63. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani N, Schooley KA, Gerhart M, Davis R, Fitzner JN, Johnson RS, Paxton RJ, March CJ and Cerretti DP: A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 385: 729-733, 1997.
64. Kawaguchi M, Mitsuhashi Y and Kondo S: Overexpression of tumour necrosis factor-alpha-converting enzyme in psoriasis. Br J Dermatol 152: 915-919, 2005.
65. Kawaguchi M, Mitsuhashi Y and Kondo S: Localization of tumour necrosis factor-alpha converting enzyme in normal human skin. Clin Exp Dermatol 29: 185-187, 2004.
66. Hooper NM, Karran EH and Turner AJ: Membrane protein secretases. Biochem J 321: 265-279, 1997.
67. Dethlefsen SM, Raab G, Moses MA, Adam RM, Klagsbrun M and Freeman MR: Extracellular calcium influx stimulates metalloproteinase cleavage and secretion of heparin-binding EGF-like growth factor independently of protein kinase C. J Cell Biochem 69: 143-153, 1998.
68. Vecchi M, Rudolph-Owen LA, Brown CL, Dempsey PJ and Carpenter G: Tyrosine phosphorylation and proteolysis. Pervanadate-induced, metalloprotease-dependent cleavage of the ErbB-4 receptor and amphiregulin. J Biol Chem 273: 20589-20595, 1998.